Mirum Pharmaceuticals, Inc. (MIRM) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 64.93M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 64.93M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 64.93M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 64.93M | (m) | (m) |
| 2026-03-31 | 60.98M | (m) | (m) |
| 2025-09-30 | 51.39M | (m) | (m) |
| 2025-06-30 | 50.24M | (m) | (m) |
| 2025-03-31 | 49.53M | (m) | (m) |
| 2024-09-30 | 48.00M | (m) | (m) |
| 2024-06-30 | 47.71M | (m) | (m) |
| 2024-03-31 | 47.13M | (m) | (m) |
| 2023-12-31 | 47.00M | (m) | (m) |
| 2023-09-30 | 46.61M | (m) | (m) |
| 2023-06-30 | 38.30M | (m) | (m) |
| 2023-03-31 | 38.03M | (m) | (m) |
| 2022-12-31 | 37.95M | (m) | (m) |
| 2022-09-30 | 36.87M | (m) | (m) |
| 2022-06-30 | 32.75M | (m) | (m) |
| 2022-03-31 | 31.84M | (m) | (m) |
| 2021-12-31 | 31.73M | (m) | (m) |
| 2021-09-30 | 30.64M | (m) | (m) |
| 2021-06-30 | 30.52M | (m) | (m) |
| 2021-03-31 | 30.45M | (m) | (m) |
| 2020-12-31 | 30.42M | (m) | (m) |
| 2020-09-30 | 25.72M | (m) | (m) |
| 2020-06-30 | 25.40M | (m) | (m) |
| 2020-03-31 | 25.39M | (m) | (m) |
| 2019-12-31 | 25.39M | (m) | (m) |
| 2019-09-30 | 22.99M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |